The role of the NY-ESO-1 in the prognosis of gastric cancer
Biomolecules and Biomedicine · 2023
DOI: 10.17305/bb.2023.9937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2023. Verfasst von Zvonimir Misir und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia. Hauptthemen laut MEDLINE: Stomach Neoplasms, Membrane Proteins, Antigens, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC) is one of the most common malignancies worldwide and the fourth leading cause of cancer-related deaths. GC is a multifactorial disease influenced by both environmental and genetic factors. Its most critical features include invasiveness and high metastatic potential. Metastasis is a complex process, and our understanding of the mechanisms involved remains incomplete. Growing evidence suggests that cancer-testis antigens (CTAs) play a crucial role in the metastatic potential of various tumors. Several studies have linked CTA expression with lower tumor differentiation, higher metastatic potential, and poor chemotherapy response. New York esophageal squamous cell carcinoma-1 (NY-ESO-1) antigen, part of the CTA group, is expressed in tumor tissues, while its expression in normal tissues is restricted to spermatogonia. This study aimed to determine the expression of NY-ESO-1 in primary adenocarcinoma of the stomach, both with and without metastasis in regional lymph nodes, and to compare it with TNM stage, age, gender, and survival. We analyzed GC tissue from 53 node-negative and 55 node-positive primary gastric carcinoma patients for NY-ESO-1 expression using immunohistochemical assay. The results were correlated with clinicopathological parameters and survival. Patients with positive NY-ESO-1 expression in primary tumors had a median survival of 19.0 months (range 14.1–24.0), in contrast to those with negative expression, who had a median survival of 52.0 months (range 0.0–133.3) (chi-square 7.99, P=0.005). T status, N status, and NY-ESO-1 expression were all independently associated with shorter survival. No significant difference in NY-ESO-1 expression in primary tumors was observed concerning lymph node metastasis status. In summary, our findings suggest that increased expression of NY-ESO-1 could potentially serve as a prognostic biomarker for GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia.
- Department of Clinical Research and Biostatistics, Poliklinika Solmed d.o.o., Zagreb, Croatia.
- Department of Gynecology, General Hospital "Dr Ivo Pedišić", Sisak, Croatia.
- Clinical Department of Pathology and Cytology "Ljudevit Jurak", University Hospital Center "Sestre milosrdnice", Zagreb, Croatia; Department of Pathology and Center of Excellence for Reproductive and Regenerative Medici…
Zitieren
APA
Misir, Z., Glavčić, G., Janković, S., Kruljac, I., Čugura Filipović, J., Čimić, K., & Ulamec, M. (2023). The role of the NY-ESO-1 in the prognosis of gastric cancer. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2023.9937
Vancouver
Misir Z, Glavčić G, Janković S, Kruljac I, Čugura Filipović J, Čimić K, et al. The role of the NY-ESO-1 in the prognosis of gastric cancer. Biomolecules and Biomedicine. 2023. doi:10.17305/bb.2023.9937
BibTeX
@article{Misir2023,
author = {Misir, Zvonimir and Glavčić, Goran and Janković, Suzana and Kruljac, Ivan and Čugura Filipović, Jakša and Čimić, Kristina and Ulamec, Monika},
title = {The role of the NY-ESO-1 in the prognosis of gastric cancer},
journal = {Biomolecules and Biomedicine},
year = {2023},
doi = {10.17305/bb.2023.9937}
}
EUVIMED